A Phase I Study of SF1126, a Dual PI3 Kinase and Bromodomain Inhibitor, in Combination With Nivolumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A-B7 Cirrhosis
Latest Information Update: 21 May 2022
At a glance
- Drugs Nivolumab (Primary) ; SF 1126 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors SignalRx Pharmaceuticals
- 11 May 2022 Status changed from active, no longer recruiting to discontinued.
- 12 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 25 May 2017 Status changed from not yet recruiting to recruiting.